Withdrawal Mgmt denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for withdrawal mgmt are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Withdrawal Management as Not FDA-Approved — and How to Appeal

Withdrawal management as a service does not itself require FDA approval — it is a clinical care process. A "not FDA-approved" denial in this context almost always targets a specific medication administered during withdrawal management that is being used in a manner not described in its FDA-approved labeling (commonly called "off-label" use). Off-label prescribing is legal, common, and often supported by clinical guidelines — but insurers may decline coverage unless the prescriber documents that the off-label use meets recognized standards of care. Humana's policy for off-label drug coverage typically requires citation of a recognized compendia or professional society guidance supporting the use. This type of denial is very frequently overturned when properly documented.

## Why This Denial Is Appealable

Not-FDA-approved or off-label denials are subject to full appeal rights. Under ACA Section 2719, non-grandfathered plan members may request independent external review after exhausting internal appeals. Under ERISA Section 503, employer-plan members are entitled to a full-and-fair internal review with a written clinical rationale. The external-review window is generally 180 days from denial; expedited 72-hour review is available when delay would jeopardize life or health. The MHPAEA prohibits applying stricter coverage restrictions to substance use disorder treatments than to comparable medical/surgical treatments — relevant if Humana covers off-label use of medications for medical conditions but restricts it for addiction medicine.

## Concrete Appeal Steps

1. Identify the specific medication and indication that Humana flagged as not FDA-approved — the denial letter must specify this. 2. Obtain Humana's off-label coverage policy — most insurers cover off-label use supported by recognized drug compendia (such as Micromedex, Drugdex, or AHFS) or major peer-reviewed literature. 3. File the internal appeal with documentation demonstrating compendia or guideline support. 4. Request peer-to-peer review so the prescriber can explain the clinical basis directly to Humana's reviewer. 5. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Diagnosis confirmation: Documented substance use disorder and specific withdrawal syndrome, with clinical notes establishing the indication for the prescribed medication.
• FDA labeling: The prescribing physician should confirm what the FDA-approved label covers and explicitly note the off-label use being requested, with the clinical rationale.
• Compendia or guideline support: The treating clinician should identify the relevant professional organization (such as ASAM or SAMHSA) and any recognized drug compendia that support this use — without quoting specific statistics, but by name.
• Clinical severity and treatment rationale: Prescriber notes explaining why FDA-labeled alternatives are insufficient or unsuitable for this specific patient's presentation.
• Prescriber medical-necessity letter: A signed letter from the treating addiction medicine specialist or physician explaining the clinical basis for the off-label use, citing the relevant compendia or guideline organization by name, and documenting that the use meets accepted standards of care.

## Criteria-Mapping Structure

Identify each criterion in Humana's off-label coverage policy. For each, cite the corresponding compendia entry, professional society guideline, or physician statement. This mapping is the core of a not-FDA-approved appeal and is what external reviewers will evaluate against the community-standard test.